Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23252547 | 0.83 | — | — | |
| SCHEMBL3842791 | 0.83 | SLC6A2 (0.30) | — | |
| SCHEMBL14553801 | 0.80 | ALDH1A1 (0.36) | ALDH1A1RAPGEF4 | |
| SCHEMBL21279544 | 0.78 | ALDH1A1 (0.33) | ALDH1A1ERN1RAPGEF4RIPK1HTT | |
| SCHEMBL12463743 | 0.78 | ERN1 (0.38) | ALDH1A1ERN1RIPK1 | |
| SCHEMBL23252538 | 0.76 | RIPK1 (0.32) | RIPK1 | |
| SCHEMBL4301635 | 0.75 | ERN1 (0.37) | ALDH1A1ERN1RAPGEF4CES2CES1 | |
| SCHEMBL18387992 | 0.74 | RIPK1 (0.36) | ALDH1A1ERN1RIPK1 | |
| SCHEMBL17278001 | 0.73 | ERN1 (0.39) | ALDH1A1ERN1RIPK1HTT | |
| SCHEMBL2097006 | 0.72 | ERN1 (0.33) | ERN1RIPK1HTTCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107592863-A | Chromium complex and olefin oligomerization catalyst therefrom with the part containing phosphorus ring | 陶氏环球技术有限责任公司 | 2018-01-16 | — | — | CN | disclosed |
| CN-107567355-A | The part containing phosphorus ring and olefin oligomerization catalyst therefrom for chromium complex | 陶氏环球技术有限责任公司 | 2018-01-09 | — | — | CN | disclosed |
| CN-107548385-A | Olefin oligomerization process using catalyst comprising chromium complex with phosphacycle-containing ligand | 陶氏环球技术有限责任公司 | 2018-01-05 | — | — | CN | disclosed |
| US-8044042-B2 | Thienotriazolodiazepine compound and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8044042-B2 | Thienotriazolodiazepine compound and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| US-6337297-B1 | CHROMIUM CATALYST FOR TRIMERIZATION OF ETHYLENE WITH MULTIDENTATE LIGAND OR HALOGEN, CARBOXY GROUP | TOSOH CORPORATION (JP) | 2002-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | ICOS, CD4, CD2 | ALDH1A1 2055/4885ERN1 4503/4885RAPGEF4 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.